Cetuximab combined with chemotherapy prolonged the overall survival of advanced NSCLC

The latest results from the FLEX trial wag presented in ASCO annual meeting which was hold in June.2008 in Chicago.The study demonstrated that chemotherapy based on Cetuximab plus Cisplatin significantly increased the overall survival of NSCLC patients,including all histological subtypes.The new findings confirm that Erbitux is the first targeted thempy to show a significant survival benefit in NSCLC patients across all histological subtypes. Key words: Carcinoma,non-small-cell lung; Targeted therapy; Antibodies,monoelonal